Wednesday, July 20, 2022 Daily Archives

Study results led to the acquisition of GeneTx, says Ultragenyx

by

Ultragenyx Pharmaceuticals has acquired GeneTx Biotherapeutics for $75 million after a program update on GTX-102, an investigational antisense oligonucleotide, revealed promising data. Ultragenyx and GeneTx partnered in 2019 to advance GTX-102, an investigational antisense oligonucleotide (ASO) that has been designed to target and prevent of expression UBE3A-AS to hinder the paternally inherited allele of the UBE3A gene and reactivate the deficient protein. It is delivered as an intrathecal infusion and aims to treat Angelman syndrome, a rare, neurogenetic disorder that is…

July 20, 2022

WuXi Biologics commits $1.4bn to Singapore manufacturing capabilities

by

WuXi Biologics will invest $1.4 billion as part of a 10-year plan to expand the company’s manufacturing capabilities in Singapore through the construction of a CDMO center. Contract development manufacturing organization (CDMO) WuXi Biologics first entered Singapore in 2018 with a $60 million clinical and commercial biologics manufacturing site expected to come online this year. Now, the firm plans to expand its research, development, and large-scale drug substance and drug product manufacturing capabilities in Singapore through a $1.4 billion investment…

July 20, 2022

International sales rise but COVID vaccine related costs mount for J&J

by

Johnson & Johnson took a $276 million hit from its COVID-19 vaccine program in its second quarter, offset by rising sales outside the US. J&J’s so-called ‘Janssen’ vaccine became the third to be approved under the FDA’s Emergency Use Authorization (EUA) in February 2021. However, in the US at least, the single-shot jab played third fiddle to Pfizer and Moderna’ mRNA vaccines leading to a drop off in demand and reports of changes in its manufacturing strategy. This drop off in…

July 20, 2022